For the quarter ending 2026-03-31, PBYI made $44,814K in revenue. -$3,753K in net income. Net profit margin of -8.37%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 44,814 | 75,453 | 54,475 | 52,436 |
| Cost of sales | 10,424 | 23,127 | 12,173 | 12,301 |
| Selling, general and administrative | 18,423 | 18,379 | 16,817 | 18,047 |
| Research and development | 19,795 | 16,841 | 15,912 | 15,452 |
| Total operating costs and expenses | 48,642 | 58,347 | 44,902 | 45,800 |
| (loss) income from operations | -3,828 | 17,106 | 9,573 | 6,636 |
| Interest income | 1,002 | 977 | 1,044 | 956 |
| Interest expense | 731 | 1,119 | 1,489 | 1,837 |
| Other income | 130 | 143 | 115 | 410 |
| Total other income (expenses), net | 401 | 1 | -330 | -471 |
| Net (loss) income before income taxes | -3,427 | 17,107 | 9,243 | 6,165 |
| Income tax expense | 326 | 424 | 399 | 310 |
| Deferred income tax (expense) benefit | - | 3,245 | - | - |
| Net (loss) income | -3,753 | 13,438 | 8,844 | 5,855 |
| Basic EPS | -0.07 | 0.267 | 0.18 | 0.12 |
| Diluted EPS | -0.07 | 0.26 | 0.17 | 0.12 |
| Basic Average Shares | 50,845,130 | 50,410,570 | 50,339,456 | 49,700,217 |
| Diluted Average Shares | 50,845,130 | 51,632,194 | 50,929,893 | 50,144,704 |
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)